首页 > 市场调查报告书 > 製药

感染疾病

抗真菌药物市场规模、份额和成长分析（按药物类别、适应症、剂型、分销管道和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1896015

抗真菌药物市场规模、份额和成长分析（按药物类别、适应症、剂型、分销管道和地区划分）—产业预测（2026-2033 年）

Antifungal Drugs Market Size, Share, and Growth Analysis, By Drug Class (Azoles, Echinocandins), By Indication (Dermatophytosis, Aspergillosis), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月15日 | 出版商:

SkyQuest | 英文 214 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，抗真菌药物市场规模将达到 155.4 亿美元，到 2025 年将达到 161.5 亿美元，到 2033 年将达到 219.3 亿美元，预测期（2026-2033 年）的复合年增长率为 3.9%。

真菌感染疾病（例如曲菌症和念珠菌症）发病率的不断上升是推动抗真菌药物市场成长的主要因素。这些感染疾病包括全身性和表浅性两种类型，可涉及皮肤、眼睛、口腔和阴道等部位。抗真菌药物，尤其是具有杀菌活性的药物，在治疗多种疾病（包括足癣、体癣和真菌性脑膜炎）方面发挥重要作用。医院感染的增加和感染疾病的流行也促进了市场扩张。真菌感染疾病是一项重大的公共卫生挑战，尤其对免疫力缺乏的人群（包括爱滋病患者）更是如此。真菌疾病的这种上升趋势凸显了对有效抗真菌疗法的巨大需求，为市场提供了强劲增长的潜力。

抗真菌药物市场驱动因素

真菌感染疾病和医院获得性感染发病率的不断上升是推动抗真菌药物市场成长的主要因素。抗真菌药物在治疗因接触医疗机构中受污染或潮湿环境而引起的全身性和表浅性性行为感染方面发挥重要作用。此外，公众和医疗专业人员对真菌感染疾病的认识不断提高，也显着推动了对这些药物的需求。随着越来越多的人和医疗机构意识到真菌感染疾病的影响，抗真菌药物市场有望在这种日益增长的认知和对有效治疗方案的需求下取得显着进展。

限制抗真菌药物市场的因素

抗真菌药物市场面临的一大挑战是真菌感染的漏诊率居高不下，这主要是由于医护人员和公众对真菌感染疾病的认识不足所造成的。这种认识不足会导致患者治疗延误，并面临治疗方案选择不足的问题。为了解决这个问题，亟需进行全面的教育活动，以提高公众意识并改善诊断方法。此外，病患与医护人员之间沟通不良和理解不足也是导致漏诊和治疗不足的原因之一。提高这方面的知识水平对于优化患者预后和更有效地治疗真菌感染疾病至关重要。

抗真菌药物市场趋势

抗真菌药物市场呈现显着上升趋势，主要得益于药物研发的不断进步。随着研究人员探索新的药物製剂、创新的给药系统和标靶治疗，更有效的治疗方案的潜力正在不断扩大。这种发展不仅改善了患者的治疗效果，也为专注于研发的製药公司创造了盈利的利润。透过专注于创新解决方案，这些公司能够满足日益增长的先进抗真菌疗法需求，尤其是在真菌感染疾病发病率上升和对传统治疗方法的抗药性日益增强的情况下。因此，市场呈现出成长迹象，而新型抗真菌药物在其中发挥关键作用。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Pfizer Inc.（US）
Gilead Sciences, Inc.（US）
Astellas Pharma Inc.（Japan）
F. Hoffmann-La Roche AG（Switzerland）
Sanofi SA（France）
Bayer AG（Germany）
Cipla Limited（India）
Hetero Labs Limited（India）
Hikma Pharmaceuticals PLC（UK）
Galderma SA（Switzerland）
Aurobindo Pharma（India）
Cipla USA Inc.（US）
Sandoz（a Novartis division）（Switzerland）
Fresenius Kabi AG（Germany）
Reddy's Laboratories Ltd.（India）
Zydus Cadila Healthcare Ltd.（India）
Eton Pharmaceuticals, Inc.（US）
Pyxis Oncology（US）
Incyte Corporation（US）

简介目录

Product Code: SQMIG35I2358

Antifungal Drugs Market size was valued at USD 15.54 Billion in 2024 and is poised to grow from USD 16.15 Billion in 2025 to USD 21.93 Billion by 2033, growing at a CAGR of 3.9% during the forecast period (2026-2033).

The growing incidence of fungal infections such as aspergillosis and candidiasis is significantly driving the antifungal drugs market. These infections encompass both systemic and superficial types, affecting areas like skin, eyes, mouth, and vagina. Antifungal medications, particularly those with fungicidal properties, are key in addressing a wide array of conditions, including athlete's foot, ringworm, and fungal meningitis. The rise in hospital-acquired infections and the prevalence of infectious diseases further contribute to market expansion. Fungal diseases present a substantial public health challenge, particularly for individuals with compromised immune systems, including those living with AIDS. This increasing burden of fungal illnesses underlines the critical demand for effective antifungal therapies, positioning the market for robust growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antifungal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antifungal Drugs Market Segments Analysis

Global Antifungal Drugs Market is segmented by Drug Class, Indication, Dosage Form, Distribution Channel, and region. Based on Drug Class, the market is segmented into Azoles, Echinocandins, Polyenes, Allylamines, and Others. Based on Indication, the market is segmented into Dermatophytosis, Aspergillosis, Candidiasis, and Others. Based on Dosage Form, the market is segmented into Oral Drugs, Ointments, Powders, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retails Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Antifungal Drugs Market

The increasing incidence of fungal and hospital-acquired infections serves as a key factor propelling the growth of the antifungal drugs market. Antifungal medications play a crucial role in treating both systemic and superficial infections, which can arise from contact with contaminated environments in healthcare settings or from humid conditions. Additionally, the expanding awareness regarding fungal diseases among the general population and healthcare professionals is significantly driving the demand for these medications. As more individuals and medical providers recognize the impact of fungal infections, the antifungal drugs market is poised for substantial advancement in response to this heightened awareness and need for effective treatment options.

Restraints in the Antifungal Drugs Market

A significant challenge in the antifungal drugs market is the frequent underdiagnosis of fungal infections, stemming from limited awareness among healthcare professionals and the general population. This lack of recognition can result in delayed, inadequate treatment options for those affected. Addressing this issue underscores the need for comprehensive educational initiatives aimed at bolstering awareness and improving diagnostic practices. Additionally, miscommunication and insufficient understanding between patients and healthcare providers can contribute to the continued prevalence of underdiagnosis and undertreatment. Enhancing knowledge in this area is crucial for optimizing patient outcomes and moving towards more effective management of fungal infections.

Market Trends of the Antifungal Drugs Market

The antifungal drugs market is witnessing a significant upward trend driven by ongoing advancements in drug development. As researchers explore new drug formulations, innovative delivery systems, and targeted therapies, the potential for more effective treatments expands. This evolution not only enhances patient outcomes but also creates lucrative opportunities for pharmaceutical companies committed to research and development. By focusing on innovative solutions, these companies can meet the growing demand for advanced antifungal therapies, especially in response to the rising incidence of fungal infections and increased resistance to traditional treatments. Consequently, the market is poised for growth, with novel antifungal agents playing a pivotal role.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition
PESTEL Analysis
FDA Approved Antifungal Drugs List
Market Attractiveness Index, 2025

Antifungal Drugs Market by Drug Class

Market Overview
Azoles
- Fluconazole
- Voricanazole
- Posaconazole
- Clotrimazole
- Others
Echinocandins
- Caspofungin
- Micafungin
- Others
Polyenes
- Amphotericin B
- Others
Allylamines
- Terbinafine
- Naftifine
- Others
Others

Antifungal Drugs Market by Indication

Market Overview
Dermatophytosis
Aspergillosis
Candidiasis
Others

Antifungal Drugs Market by Dosage Form

Market Overview
Oral Drugs
Ointments
Powders
Others

Antifungal Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retails Pharmacies
Others

Antifungal Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hetero Labs Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galderma S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla USA Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (a Novartis division) (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila Healthcare Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eton Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pyxis Oncology (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments